• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4597351)   Today's Articles (5549)   Subscriber (49349)
Number Citation Analysis
101
Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, Bozzetti C, Sammarelli G, Thai E, Ardizzoni A. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 2010;71:241-3. [PMID: 21168933 DOI: 10.1016/j.lungcan.2010.11.014] [Citation(s) in RCA: 88] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2010] [Revised: 10/30/2010] [Accepted: 11/21/2010] [Indexed: 10/18/2022]
102
Musolino A, Michiara M, Conti GM, Boggiani D, Bozzani F, Zatelli M, Sgargi P, Ardizzoni A. Abstract P2-04-01: HER2 Status as Predictor of Mammographic Screening Detection: Comparison of Interval-and Screen-Detected Breast Cancers. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-04-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
103
Musolino A, Bisagni G, De Matteis A, Nuzzo F, Ardizzoni A, Crinò L, Gamucci T, Passalacqua R, Gnoni R, Boni C. Abstract P2-17-01: Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-17-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
104
Negri FV, Bozzetti C, Lagrasta CA, Crafa P, Bonasoni MP, Camisa R, Pedrazzi G, Ardizzoni A. PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 2009;102:162-4. [PMID: 19953097 PMCID: PMC2813733 DOI: 10.1038/sj.bjc.6605471] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]  Open
105
Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, De Lisi V, Ardizzoni A. 5187 Multifactorial CNS relapse susceptibility in HER-2-positive breast cancer patients: first results from a population-based registry study. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71079-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]  Open
106
Soto Parra HJ, Ippolito M, Tiseo M, Cosentino S, Ardizzoni A, Latteri F, Pumo V, Cordio S, Bordonaro R, Spadaro P. Usefulness of 18FDG-positron emission tomography (FDG-PET) for early prediction of erlotinib (Eb) treatment outcome in non-small cell lung cancer (NSCLC) patients: Results of a pilot study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7568] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
107
Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, De Lisi V, Sgargi P, Ceci G, Ardizzoni A. Multifactorial CNS relapse susceptibility in HER2-positive breast cancer patients: First results from a population-based registry study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
108
Ardizzoni A, Capuccini B, Baschieri MC, Orsi CF, Rumpianesi F, Peppoloni S, Cermelli C, Meacci M, Crisanti A, Steensgaard P, Blasi E. A protein microarray immunoassay for the serological evaluation of the antibody response in vertically transmitted infections. Eur J Clin Microbiol Infect Dis 2009;28:1067-75. [PMID: 19415353 DOI: 10.1007/s10096-009-0748-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2009] [Accepted: 04/15/2009] [Indexed: 02/02/2023]
109
Amadori D, Gasparini G, Ardizzoni A, Comella G, Saracchini S, Barone C, Bordonaro R, Djazouli K, Barbato A. Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-3149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
110
De Filippo M, Onniboni M, Rusca M, Carbognani P, Ferrari L, Guazzi A, Casalini A, Verardo E, Cataldi V, Tiseo M, Sverzellati N, Chiari G, Rabaiotti E, Corsi A, Cacciani G, Sommario M, Ardizzoni A, Zompatori M. Advantages of multidetector-row CT with multiplanar reformation in guiding percutaneous lung biopsies. Radiol Med 2008;113:945-53. [PMID: 18818985 DOI: 10.1007/s11547-008-0325-y] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2008] [Accepted: 02/25/2008] [Indexed: 12/20/2022]
111
Cascinu S, Berardi R, Salvagni S, Beretta GD, Catalano V, Pucci F, Sobrero A, Tagliaferri P, Labianca R, Scartozzi M, Crocicchio F, Mari E, Ardizzoni A. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Br J Cancer 2007;98:71-6. [PMID: 18059397 PMCID: PMC2359708 DOI: 10.1038/sj.bjc.6604121] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]  Open
112
Vasini G, Bacchini G, Franciosi V, Ghidini C, Musolino A, Camisa R, Meschi T, Borghi L, Ardizzoni A. 1134 POSTER Survival prediction of terminally ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70653-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]  Open
113
Tiseo M, Franciosi V, Ardizzoni A. Multi-target inhibitors in non-small cell lung cancer (NSCLC). Ann Oncol 2007;17 Suppl 2:ii55-57. [PMID: 16608985 DOI: 10.1093/annonc/mdj924] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
114
Gatzemeier U, Ardizzoni A, Horwood K, van Meerbeeck J, Magyar P, Gottfried M, Arrieta O, Krzakowski M, Franke F, van Zandwijk N. Erlotinib in non-small cell lung cancer (NSCLC): Interim safety analysis of the TRUST study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7645] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
115
Bruzzi P, Sormani M, Tiseo M, Boni L, Rosell R, Ardizzoni A. Tumor response to chemotherapy as a surrogate endpoint of survival in advanced non-small cell lung cancer (NSCLC): Results of an individual patients data meta-analysis. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
116
Bozzetti C, Tiseo M, Lagrasta C, Nizzoli R, Leonardi F, Gasparro D, Spiritelli E, Franciosi V, Rindi G, Ardizzoni A. Comparison between epidermal growth factor receptor (EGFR) gene in primary non-small cell lung cancer (NSCLC) and in fine needle aspirates from metastatic sites. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.21081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
117
Musolino A, Guazzi A, Lazzaretti M, Pezzuolo D, Calzetti C, Degli Antoni A, Ardizzoni A. Intracranial hematopoiesis in a patient with aids-related central nervous system lymphoma and severe pancytopenia. Haematologica 2007;92:e59-61. [PMID: 17562595 DOI: 10.3324/haematol.11419] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]  Open
118
Beretti F, Cenacchi V, Portolani M, Ardizzoni A, Blasi E, Cermelli C. A Transmissible Cytotoxic Activity Isolated from a Patient with Brain Ischemia Causes Microglial Cell Activation and Dysfunction. Cell Mol Neurobiol 2007;27:517-28. [PMID: 17380379 DOI: 10.1007/s10571-007-9142-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2006] [Accepted: 02/14/2007] [Indexed: 01/04/2023]
119
Musolino A, Naldi N, Bortesi B, Capelletti M, Pezzuolo D, Missale G, Laccabue D, Camisa R, Franciosi V, Ardizzoni A. Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13090] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
120
Belvedere O, Sacco C, Ardizzoni A, Rossetto C, Follador A, Sibau A, Tumolo S, Defferrari C, Fasola G, Grossi F. Second line chemotherapy with topotecan and gemcitabine in small cell lung cancer (SCLC) patients: An Alpe-Adria Thoracic Oncology Multidisciplinary group phase II study (ATOM 012). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
121
Ardizzoni A, Tiseo M, Boni L, Rosell R, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Mazzanti P, Bisset D. CISCA (cisplatin vs. carboplatin) meta-analysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7011] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
122
Ardizzoni A, Tiseo M. Novel targeted approaches in non-small cell lung cancer (NSCLC). Ann Oncol 2006;17 Suppl 5:v91-3. [PMID: 16807473 DOI: 10.1093/annonc/mdj959] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
123
Tiseo M, Franciosi V, Grossi F, Ardizzoni A. Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice? Eur J Cancer 2006;42:8-16. [PMID: 16293409 DOI: 10.1016/j.ejca.2005.08.031] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2005] [Accepted: 08/09/2005] [Indexed: 11/20/2022]
124
Tiseo M, Tognoni A, Carob C, Mencoboni M, Pennucci M, Coialbu T, Brema F, Grossi F, Pronzato P, Ardizzoni A. P-584 Single agent gemcitabine (GEM) in performance status (PS) 2–3patients (pts) with advanced non-small cell lung cancer (NSCLC): Effect on disease-related symptoms in a multicenter phase II trial. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)81077-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
125
Porta C, Ardizzoni A, Gaudino G, Maio M, Mutti L, Pinto C, Porru S, Puntoni R, Tassi G, Tognon M. Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group. LA MEDICINA DEL LAVORO 2005;96:360-9. [PMID: 16457433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
PrevPage 5 of 11 124561011Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA